Current Evidence on the Relationships Among Five Polymorphisms in the Matrix Metalloproteinases Genes and Prostate Cancer Risk

Overview

Journal Sci Rep

Specialty Science

Date 2024 May 18

PMID 38762659

Authors

Jiandong Gui

Hangsheng Zhou

Sixin Li

Anjie Chen

Qing Liu

Lijie Zhu

Yuanyuan Mi

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs) had a variety of subtypes, which may be related to tumor invasion and angiogenesis, and the polymorphisms from MMPs have been also associated with the susceptibility to a variety of tumors, including prostate cancer (PCa). However, previous studies have not systematically analyzed the association between MMP and prostate cancer, so we conducted systematic data collection and analyzed to evaluate the relationship among polymorphisms in MMPs and PCa susceptibility. We searched PubMed, Web of Science, Embase and Google Scholar for all papers published up to Apr 3rd, 2023, and systematically analyzed the relationship among MMP1-1607 2G/1G, MMP2-1306 T/C, MMP2-735 T/C, MMP7-181 G/A, MMP9-1562 T/C and PCa susceptibility using multiple comparative models and subgroup analyses. We found that MMP2-1306 T/C polymorphism showed associations with PCa susceptibility, with the Ethnicity subgroup (Asian) being more pronounced. Similarly, MMP9-1562 T/C has also had associations with PCa susceptibility. Our current study found that the polymorphisms of, MMP2-1306 T/C, and MMP9-1562 T/C had strong associations with PCa risk.

References

Reis S, Villanova F, de Andrade P, Pontes J, Silva I, Canavez F . Polymorphisms of the matrix metalloproteinases associated with prostate cancer. Mol Med Rep. 2011; 1(4):517-20. View

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

Roh J, Muelleman T, Tawfik O, Thomas S . Perineural growth in head and neck squamous cell carcinoma: a review. Oral Oncol. 2014; 51(1):16-23. PMC: 4268058. DOI: 10.1016/j.oraloncology.2014.10.004. View

Ganguly S, Hostetter G, Tang L, Frank S, Saboda K, Mehra R . Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. Oncogene. 2019; 39(1):204-218. PMC: 6938550. DOI: 10.1038/s41388-019-0977-1. View

Liao C, Wu H, Hu P, Hsu S, Shen T, Hsia T . The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients. Anticancer Res. 2018; 38(7):3907-3911. DOI: 10.21873/anticanres.12675. View

Weng H, Zeng X, Wang X, Liu T, He D . Genetic Association between Gene Polymorphisms and Risk of Prostate Cancer: A Meta-Analysis. Front Physiol. 2017; 8:975. PMC: 5717537. DOI: 10.3389/fphys.2017.00975. View

Snyman M, Xu S . The effects of mutations on gene expression and alternative splicing. Proc Biol Sci. 2023; 290(2002):20230565. PMC: 10320348. DOI: 10.1098/rspb.2023.0565. View

Shajarehpoor Salavati L, Tafvizi F, Manjili H . The association between MMP2 -1306 C > T (rs243865) polymorphism and risk of prostate cancer. Ir J Med Sci. 2016; 186(1):103-111. DOI: 10.1007/s11845-016-1492-9. View

Gronberg H, Damber L, Damber J . Studies of genetic factors in prostate cancer in a twin population. J Urol. 1994; 152(5 Pt 1):1484-7; discussion 1487-9. DOI: 10.1016/s0022-5347(17)32452-7. View

10.

Adabi Z, Mohsen Ziaei S, Imani M, Samzadeh M, Narouie B, Jamaldini S . Genetic Polymorphism of MMP2 Gene and Susceptibility to Prostate Cancer. Arch Med Res. 2015; 46(7):546-50. DOI: 10.1016/j.arcmed.2015.08.004. View

11.

Faivre E, McDaniel K, Albert D, Mantena S, Plotnik J, Wilcox D . Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020; 578(7794):306-310. DOI: 10.1038/s41586-020-1930-8. View

12.

Trudel D, Fradet Y, Meyer F, Harel F, Tetu B . Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003; 63(23):8511-5. View

13.

Liu K, Gu S, Liu X, Sun Q, Wang Y, Meng J . The rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis. Oncotarget. 2017; 8(42):72933-72938. PMC: 5641180. DOI: 10.18632/oncotarget.18014. View

14.

Zhou H, Zhu X . Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review. Cancer Manag Res. 2018; 10:5247-5259. PMC: 6223342. DOI: 10.2147/CMAR.S177551. View

15.

Zhang K, Chen X, Zhou J, Yang C, Zhang M, Chao M . Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: a meta-analysis based on 3906 subjects. Oncotarget. 2017; 8(27):45020-45029. PMC: 5546537. DOI: 10.18632/oncotarget.16972. View

16.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

17.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

18.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

19.

Yaykasli K, Kayikci M, Yamak N, Soguktas H, Duzenli S, Arslan A . Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer. Turk J Med Sci. 2014; 44(5):839-43. View

20.

Meng J, Wang S, Shen X, Bai Z, Niu Q, Ma D . Polymorphism of MMP-9 gene is not associated with the risk of urinary cancers: Evidence from an updated meta-analysis. Pathol Res Pract. 2018; 214(12):1966-1973. DOI: 10.1016/j.prp.2018.09.011. View